Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma

NCT01663012 is registered in ClinicalTrials.gov with Lawrence Recht as lead sponsor.

NCT NCT01663012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01663012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Lead sponsor
Lawrence Recht
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
February 28, 2015
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytomas, anaplastic oligodendrogliomas, glioblastomas (gbm)